Zevtera Ceftobiprole Medocaril Sodium for Injection

1. Indications and Usage
Staphylococcus aureus Bloodstream Infections: Treatment of adult patients with S. aureusbloodstream infections (SAB), including right-sided infective endocarditis caused by methicillin-sensitive and methicillin-resistant isolates.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Treatment of adult patients with ABSSSI caused by susceptible strains of Gram-positive and Gram-negative microorganisms.
Community-Acquired Bacterial Pneumonia (CABP): Treatment of adult and pediatric patients (≥3 months) with CABP caused by susceptible pathogens.
2. Dosage and Administration
Route of Administration: For Intravenous (IV) Use ONLY.
Recommended Dosage:
Adults: 500 mg (equivalent to 667 mg ceftobiprole medocaril sodium) administered every 12 hours.
Pediatrics: Dosing is weight-based and varies by age bracket for CABP.
Critical Administration Instructions:
Preparation: Reconstitute with Sterile Water for Injection, then further dilute in 0.9% Sodium Chloride or 5% Dextrose.
Infusion Time: Administer over approximately 2 hours. Do not administer as an IV bolus.
Renal Impairment: Dose adjustment is mandatory for patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease.
3. Mechanism of Action
PBP Binding: Ceftobiprole binds with high affinity to penicillin-binding proteins (PBPs), particularly PBP2a in methicillin-resistant Staphylococcus aureus (MRSA).
Cell Wall Inhibition: It irreversibly inhibits bacterial cell wall synthesis, leading to cell death.
Prodrug Conversion: Ceftobiprole medocaril sodium is a prodrug that is rapidly hydrolyzed by non-specific plasma esterases into the active compound, ceftobiprole.
4. Safety and Warnings
Hypersensitivity: Contraindicated in patients with severe hypersensitivity to ceftobiprole, other cephalosporins, or penicillins.
Seizures and CNS Toxicity: Seizures and other CNS adverse reactions (e.g., non-convulsive status epilepticus) have been reported, particularly in patients with renal impairment or pre-existing seizure disorders.
Clostridioides difficile-Associated Diarrhea: Use may lead to C. difficile infection, ranging from mild diarrhea to fatal colitis.
VAP Mortality: Not approved for Ventilator-Associated Bacterial Pneumonia (VABP) due to increased mortality in a clinical subgroup.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Nausea, diarrhea, headache, increased liver enzymes (ALT/AST), vomiting, and injection site reactions.
Clinical Research Highlights: Pivotal trials (e.g., TESTIMONY) demonstrated non-inferiority to vancomycin with aztreonam for SAB, with significant advantages in clinical cure rates for MRSA infections.
6. Drug Interactions
OATP1B1/OATP1B3 Substrates: Ceftobiprole may increase plasma concentrations of co-administered drugs that are substrates of these hepatic uptake transporters.
Diagnostic Interference: May cause false-positive results in urine dipstick tests for protein, ketone, or occult blood.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Ceftobiprole medocaril sodium (prodrug).
Appearance: White to off-white lyophilized powder or cake.
Packaging: Single-use vial (667 mg ceftobiprole medocaril sodium equivalent to 500 mg ceftobiprole).
Storage: Store in the original carton at 2°C to 8°C. Protect from light.